A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease. |
Ongoing |
Sevuparin |
2 |
TVOC01 |
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), Qatif Central Hospital |
A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients with MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age |
Ongoing |
Elaprase |
4 |
SHPELA401 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
"CLCZ696B2401-TRANSITION (A multicenter, randomized, open label, parallel group studycomparing pre-discharge and posT-discharge tReatmentinitiation with LCZ696 in heArt failure patieNtS withreduced ejectIon-fracTion hospItalized for an acutedecOmpensation eveNt (ADHF)" |
Ongoing |
Entresto (SACUBITRIL, VALSARTAN) |
4 |
CZ696B2401 |
Saud Al-Babtain Cardiac Center (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah), King Faisal Specialist Hospital and Research Center (Riyadh), King Khalid University Hospital (Riyadh) |
A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF USING TOCILIZUMAB (TCZ) FOR CONFIRMED RHEUMATOID ARTHRITIS (RA) PATIENTS IN CLINICAL PRACTICE |
Ongoing |
tocilizumab |
4 |
ML299336 |
King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh) |
"A Randomized controlled Trial of Influenza Vaccineto Reduce Adverse Vascular Events" |
Ongoing |
Vaxigrip |
3 |
version 2 |
King Khalid University Hospital (Riyadh), King Abdulaziz University Hospital (Jeddah), King Fahad Medical City (Riyadh), Madinah Cardiac Center |
"A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition tothe Paliperidone Palmitate 3-Month Formulation in Patients with SchizophreniaPreviously Stabilized on the Paliperidone Palmitate 1-Month Formulation" |
Ongoing |
paliperidone |
3 |
R092670SCH3015 |
Jeddah psychiatric hospital, Al-Amal Complex for mental health (Dammam) |
"Study H9X-MC-GBGC is a Phase 3, randomized, double-blind, placebo-controlled trial withan open-label extension that investigates the effect of the addition of dulaglutide (0.75 and1.5 mg/week) or placebo weekly to metformin and/or basal insulin on change from baselinein hemoglobin A1c at 26 weeks in children and adolescents with type 2 diabetes mellitus" |
Ongoing |
Dulaglutide 0.75 /1.5 mg |
3 |
H9X-MC-GBGC |
King Khalid University Hospital (Riyadh), International Medical Center (Jeddah) |
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity |
Ongoing |
Ranibizumab |
3 |
CRFB002H2301 V 01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
RAINBOW study: a randomized, controlled study evaluating the efficacy and safety of Ranibizumab compared with laser therapy for the treatment of Infants BOrn prematurely With retinopathy of prematurity |
Ongoing |
Ranibizumab |
3 |
CRFB002H2301 V 01 |
King Faisal Specialist Hospital and Research Center (Riyadh) |
Phase 2 study of 5 Days azacytidine priming prior to fludarabine, cytarabine and G-CSF combination for patients with relapsed or refractory AML. |
Ongoing |
Vidaza |
2 |
Version 1.1 |
King Fahad Medical City (Riyadh) |